VIVS VivoSim Labs, Inc.

$VIVS So it seems we were subject to a coordinated naked short stock raid on July 16th. The float was about 10-12m after dilution, and over 9m shares failed to deliver. They shorted almost the whole float over. I'm fucking furious. I wouldn't be surprised if they're still doing it to ensure the stock goes to OTC or has to RS, thus eroding further shareholder confidence. Absolutely atrocious behaviour.

$VIVS Lowered my average for the 8th time since my entry in 2016. Now down to $7.50 from $14. Tiny sum though, so its easy.

$VIVS These prices at these levels won't be here for much longer. VivoSim already has paying Chinese customers. Two initial programs came from: A Shanghai-based oncology biotech A Chengdu-based pharmaceutical company And the orders aren't just for basic testing. They include: GI toxicology screening GI efficacy profiling $BIVI $SLS $HOWL $IVF

$VIVS they just dipped her .26 on decent news….. added Long term account as we wait. Nice volume PM

$VIVS With the 8k on August 21,the company was granted an additional 180days to get compliant .

$VIVS CCO just bought 10K shares,I think more insiders will start buying could be a sign of things to come.

$VIVS Just a little spark could cause a wildfire 🔥. The most valueable Pharmaceutical institution is linked to VIVS - LILLY. This could go bananas once people find this. $AEHL $NCRA $RDHL $WETO

$VIVS I like it‼️ On March 25, 2025, we sold our FXR program and related assets to Eli Lilly and Company (the “FXR Asset Sale”). The consideration for the FXR Asset Sale included potential milestone payments by Eli Lilly and Company of up to $50.0 million in the aggregate, which are contingent upon the achievement of certain development, regulatory and commercial milestones. In July 2026, we received a milestone payment in the amount of $5.0 million upon the achievement of a certain development milestone related to the FXR Asset Sale; however, there can be no assurance that we will be entitled to receive any additional milestone payments, and there is risk that any or all of the remaining milestone events may not be achieved, that disagreements may occur regarding the achievement of such milestones and that any or all of the remaining payments tied to the achievement of the milestone events might not be received.

$VIVS NAMkind Human Liver Tissue is protected by U.S. Patent Nos. 9,222,932, 9,442,105, 10,400,219 and 11,127,774; Australia Patent Nos. 2014236780 and 2017200691; Canada Patent No. 2,903,844; and European Patent No. 2970896. Our Human Kidney Tissue is protected by U.S. Patent Nos. 9,481,868, 10,094,821, 10,962,526 and 11,867,689; Australian Patent No. 2015328173; Canadian Patent No. 2,962,778; Chinese Patent No. ZL201580066469.8; European Patent No. 3204488; and Japan Patent No. 7021177. These issued patents and pending patent applications carry remaining patent terms ranging from over 10 years to just over 8 years. We currently have several patents and pending patent applications in the U.S. and globally that are directed to additional features on bioprinters, additional tissue types, their methods of fabrication, and specific applications

$VIVS In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided with an initial period of 180 calendar days, or until February 16, 2027, to regain compliance. Time for the company to roast da shorts!

$VIVS VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs

$VIVS VivoSim Labs Expands Asia-Pacific Access Key Partnership Details South Korea Partner: JCBio was appointed as an authorized distributor to bring human-based toxicology platforms to the Korean market. Core Offering: The distribution covers NAMKind toxicology services focusing on the human liver and small intestine. How the Platform Works Model: Uses a "molecules in, data out" framework. Speed: Targets a 30-day turnaround time per test compound. Goal: Helps pharmaceutical developers spot toxicity issues early without relying solely on animal testing. Why the APAC Market Matters South Korea: Local regulators (MFDS) are increasingly aligning with U.S. FDA standards to accept non-animal New Approach Methodologies (NAMs).

$VIVS I don’t see it regaining compliance but I do think a couple liquid pumps will happen before RS

$VIVS the future is looking bright. Stay alert Stay strapped in The sleepy phase is over

$VIVS Wow. It's up less than half a penny after going down over twenty cents and these ppl are all excited. Sheesh. Gotta do better that that.

Yesterday's Recap: $VIVS Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026 $ANY Completes Rebrand as DarkHorse Technologies Inc. $CBDW Signs LOI for Potential Transaction Involving Texas Power Plant and Data Center Project $GMGMF Gen 2.0 Graphene Manufacturing Plant

$VIVS Today's news is neutral to slightly positive and should not affect the stock price significantly. The stock is down right now because traders who bought high in premarket are trying to exit. Last offering was at $0.85 per share in July. On August 31, their Chief Commercial Officer purchase 10,000 shares at $0.2804 per share. Armistice Capital owns 10.47%. They have a reasonable cash runway. They may receive up to $45 million in future commercial milestone payments from Eli Lilly related to the sale of their inflammatory bowel disease drug program. The company market cap ($4.3 million on my broker) is well below potential receipts from Eli Lilly. They may announce new commerical contracts at any time, especially in 2027. They recently added two customers in China. I'm not particularly excited about their business model, hard to know when they will be profitable. Seems like their services are too cheap.

$VIVS this technology has real value imo, sparing animals from needless suffering and reducing risk from new medicines.

$VIVS someone desperately trying to keep this locked down here….. bring the buying pressure!!

$VIVS We might see something here building something useful Here’s why 🔹 Expanding the platform Just announced plans to develop a **rat liver model** 🔹 Complements their existing **NAMkind human liver platform** 🔹 Broader toxicology offering Gives pharma more tools under one roof 🔹 More capabilities = more contracts Higher value for customers who still use traditional models They’re building a full suite, not just one product. $GPRO $LIDR $RITR $HKPD